CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Response: Comparison of the Efficacy of Octreotide Long-acting Repeatable and Lanreotide Autogel in Acromegalic Patients (J Korean Endocr Soc 25:37-45, 2010).
Seul Young Kim, Dohee Kim
Endocrinol Metab. 2010;25(2):159-160.   Published online June 1, 2010
DOI: https://doi.org/10.3803/EnM.2010.25.2.159

Excel Download

Response: Comparison of the Efficacy of Octreotide Long-acting Repeatable and Lanreotide Autogel in Acromegalic Patients (J Korean Endocr Soc 25:37-45, 2010)
Endocrinology and Metabolism. 2010;25(2):159   Crossref logo
Link1 Link2 Link3

Letter: Comparison of the Efficacy of Octreotide Long-acting Repeatable and Lanreotide Autogel in Acromegalic Patients (J Korean Endocr Soc 25:37-45, 2010)
Endocrinology and Metabolism. 2010;25(2):157   Crossref logo
Link1 Link2 Link3

Comparison of the Efficacy of Octreotide Long-acting Repeatable and Lanreotide Autogel in Acromegalic Patients
Journal of Korean Endocrine Society. 2010;25(1):37   Crossref logo
Link1 Link2 Link3

Comparison of the Efficacy of Octreotide Long-acting Repeatable and Lanreotide Autogel in Acromegalic Patients
Journal of Korean Endocrine Society. 2010;25(1):25   Crossref logo
Link1 Link2 Link3

Efficacy of a slow-release formulation of lanreotide (Autogel® 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study
Yearbook of Endocrinology. 2008;2008:330-331   Crossref logo
Link1 Link2

Efficacy of a slow-release formulation of lanreotide (Autogel® 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study
Yearbook of Medicine. 2008;2008:560-561   Crossref logo
Link1 Link2

A 12‐month randomized crossover study on the effects of Lanreotide Autogel and Octreotide long‐acting repeatable on GH and IGF‐l in patients with acromegaly
Clinical Endocrinology. 2007;68(3):473-480   Crossref logo
Link1 Link2 Link3 Link4

Efficacy of a slow-release formulation of lanreotide (Autogel®120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study
Clinical Endocrinology. 2007;67(4):512-519   Crossref logo
Link1 Link2

Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study
Clinical Endocrinology. 1999;51(2):159-164   Crossref logo
Link1 Link2 Link3

Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials
Pituitary. 2018;21(3):283-289   Crossref logo
Link1 Link2 Link3